VarmX secures US approval to begin phase 3 trial of urgent surgery treatment
Pharma Times
JULY 8, 2025
The study will evaluate how effectively VMX-C001 restores blood clotting in emergency surgical settings. The decision enables the launch of the global EquilibriX-S trial later this year, spanning more than 20 countries. VMX-C001 is a modified human factor X protein engineered to bypass the effects of FXa DOACs.
Let's personalize your content